Colon Tumors That Spread Sideways Already Carry a Cancer-Like Gut Signature

Not every precancerous growth in the colon looks or behaves the same way, and a new multi-omics study zooms in on one specific, easy-to-miss type: laterally spreading tumors (LSTs, flat lesions that creep sideways along the colon lining instead of growing into a raised polyp). Because of their flat shape, LSTs are more likely to be overlooked during a colonoscopy than an ordinary polyp, and until recently the molecular landscape of these lesions has remained comparatively understudied next to conventional adenomas (garden-variety precancerous polyps) or full-blown colorectal cancer. This is a different question from the broad, population-spanning colorectal cancer microbiome signatures making headlines elsewhere; this study asks specifically what is happening, biologically, inside LSTs themselves, using gut bacteria, blood chemistry, and microbial genetics together rather than any one of those alone.

Key takeaways

• A multi-omics study of 35 matched laterally spreading tumor (LST) patients and 35 healthy controls found a coordinated shift, called a carcinogenic eco-metabolic shift (CES), across gut bacteria, microbial genetic functions, and blood metabolites.
• This is a different, narrower finding than the broad multi-country colorectal cancer microbiome signatures already reported elsewhere; LSTs are flat, precancerous lesions, not established cancer.
• A compact five-marker version of the signature, including depleted Roseburia and elevated blood succinate, captured most of the pattern, and an external 2,340-sample dataset placed the microbial piece along a trajectory toward the colorectal-cancer-associated state.
• The study is observational, single-center, and explicitly cannot establish causation; the CES score is a research summary measure, not a diagnostic test.

A Coordinated "Carcinogenic Eco-Metabolic Shift" in Laterally Spreading Tumors

Patients with laterally spreading tumors showed a coordinated pattern the researchers call a carcinogenic eco-metabolic shift (CES, a combined signal across gut bacteria, their genetic functions, and blood chemistry that tracks toward a cancer-like state), published in Frontiers in Microbiology. The shift involved three things moving together in the same direction: a drop in protective, fermentation-based gut bacteria; a rise in facultative bacteria (opportunistic species that can survive with or without oxygen, associated with disease-prone gut states) and known pathobionts (bacteria capable of causing harm under the right conditions); and a remodeling of blood metabolites tied to energy metabolism and amino acids. When the researchers compressed this into a compact five-marker version, using depletion of the beneficial bacterium Roseburia, elevated blood succinate, elevated microbial carbohydrate-uptake activity (PTS, phosphotransferase system), depleted 3-hydroxybutyric acid, and enrichment of Escherichia (a genus that includes E. coli), that five-marker signature preserved the overall pattern.

Why This Matters for Anyone Managing Colon Health

Laterally spreading tumors matter to anyone already thinking about colon cancer screening or managing a personal or family history of colorectal polyps, because their flat, spreading shape makes them one of the lesion types most likely to be missed on a standard colonoscopy, and because until now it has been unclear whether their underlying biology looks more like an ordinary adenoma or something closer to cancer. This study is explicitly not the same finding as the large, multi-country studies that have identified a broad "universal" microbial signature across colorectal cancer patients globally; that work describes fully developed cancer across large international cohorts, while this study is narrower and earlier in the disease process, focused specifically on a premalignant, non-cancerous lesion type, an area systematically reviewed elsewhere for precancerous colorectal lesions but rarely broken down by lesion subtype like LSTs specifically. The value here is in showing that even before a lesion becomes cancer, its surrounding gut and blood chemistry may already be shifting in a cancer-associated direction, in this one specific lesion type.

How the Researchers Tested the Signal, and Checked It Against Outside Data

The core analysis used a cohort of 63 patients with laterally spreading tumors and 85 healthy controls, propensity-score matched down to 35 patients and 35 controls each to control for age, sex, and BMI, drawing on the authors' previously reported LST cohort. The team combined stool shotgun metagenomic sequencing (to profile gut bacteria and their genetic functions), serum metabolomics (blood chemistry), and functional gene analysis (KEGG pathways, a standard catalog of what microbial genes actually do) into the single CES score. To check whether the microbial piece of that signature fit into the known colorectal disease progression, they compared it against a public reference dataset of 2,340 stool samples pooled from 15 cohorts across 10 countries. In that external comparison, colorectal cancer patients had significantly higher microbial CES scores than both healthy controls and adenoma patients, while healthy controls and adenoma patients did not differ significantly from each other, situating the LST-associated signature along a trajectory that tracks toward, though does not equal, the cancer-associated microbial state. Within the matched LST cohort itself, the paired, integrated CES score (combining stool, serum, and functional data in the same patients) separated LST patients from healthy controls with a rank-biserial effect size of 0.952, a large, consistent separation between the two groups on this composite measure.

What This Signature Does and Does Not Tell You Right Now

This is not a diagnostic test, and the authors are explicit that the CES score is "a quantitative summary rather than a diagnostic model," not something trained or validated to flag individual patients in a clinic today. Nobody should expect a doctor to order a CES score test alongside a colonoscopy on the strength of this study. What it does offer is a research signal: a coordinated, cross-layer biological pattern, gut bacteria, their functions, and blood chemistry, moving together in laterally spreading tumors specifically, that the authors say is worth developing further as a framework for understanding which flat colon lesions are biologically closer to the cancer end of the spectrum. If you are someone managing polyp history or colorectal cancer risk, the practical takeaway is not a new test to ask for; it is that flat, laterally spreading lesions may deserve to be tracked as biologically distinct from ordinary polyps in future microbiome research, and, as always, screening adherence and following up on any flagged lesion with your gastroenterologist remains the actionable step today.

Why This Cannot Prove Bacteria Cause the Tumor Shift

The authors are direct about the limits of this study: it was observational and single-center, and it "could not establish causal relationships among microbial taxa, microbial functions, serum metabolites, and LST development." The succinate and related metabolite signals, they caution, "should not be overinterpreted as proof of a single pathway or causal direction" and are better read as correlated markers than as proof of mechanism. The study also did not systematically collect dietary history, so diet as a confounding factor behind both the gut bacteria shifts and the blood chemistry changes cannot be ruled out, and the external validation dataset only had stool microbiome data available, not the matching blood metabolite or genetic-function layers, so that comparison is described by the authors as disease-sequence context rather than full multi-omics replication.

What Would Need to Happen Next

The authors describe this explicitly as a first, testable framework rather than a finished result, and they call for validation in larger, multi-center cohorts that include healthy controls, conventional adenomas, serrated lesions (another distinct precancerous lesion subtype), other LST subtypes, and colorectal cancer cases all studied under the same conditions. They also flag longitudinal sampling before and after surgical removal of these lesions, and targeted experimental models, as the next step needed to figure out whether this eco-metabolic shift is a driver of the tumor's development, a passenger effect, or simply a downstream consequence of the tumor already being there.

Common Questions

What is a laterally spreading tumor? It is a flat, non-polypoid precancerous growth in the colon that spreads sideways along the lining rather than forming a raised polyp, which makes it more likely to be missed during a standard colonoscopy than an ordinary adenoma.

Is this the same as the recent colorectal cancer gut bacteria study covering many countries? No. Broader studies have described a shared microbial signature across colorectal cancer patients internationally; this study is narrower, focused specifically on laterally spreading tumors, a premalignant lesion type, using a combined gut bacteria, blood chemistry, and genetic-function score rather than gut bacteria alone.

Can this CES score be used as a test today? No. The authors describe it explicitly as a quantitative summary measure for research purposes, not a validated diagnostic test, and they call for further validation before it could be used clinically.

Does this study prove gut bacteria cause these tumors to form? No. It is an observational, single-center study, and the authors state directly that it cannot establish causal relationships between the microbial and metabolic changes and tumor development.

References

1. Wenming Liu, Jie Liu, Yudai Chen, et al. (2026). Colorectal laterally spreading tumors exhibit a distinct carcinogenic eco-metabolic shift defined by multi-omics profiling. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2026.1887252
2. Mara Martinelli, Nicoletta Cascelli, Ottavia Bartolo, et al. (2025). The Molecular Landscape of Colorectal Laterally Spreading Tumors: From Endoscopic Subtypes to Molecular Targets. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178445
3. Hao Lin, Yudai Chen, Ming Zhou, et al. (2025). Comprehensive analysis of faecal metagenomic and serum metabolism revealed the role of gut microbes and related metabolites in detecting colorectal lateral spreading tumours. Virulence. https://doi.org/10.1080/21505594.2025.2489154